Edition:
India

Mallinckrodt Plc (MNK.N)

MNK.N on New York Stock Exchange

35.93USD
1:23am IST
Change (% chg)

$-0.14 (-0.39%)
Prev Close
$36.07
Open
$36.55
Day's High
$36.55
Day's Low
$35.19
Volume
529,752
Avg. Vol
818,570
52-wk High
$41.65
52-wk Low
$11.66

Latest Key Developments (Source: Significant Developments)

Mallinckrodt Names Paul Carter, Anne Whitaker To Its Board Of Directors
Wednesday, 4 Apr 2018 

April 4 (Reuters) - Mallinckrodt Plc ::MALLINCKRODT NAMES PAUL R. CARTER, ANNE C. WHITAKER TO ITS BOARD OF DIRECTORS.PAUL R. CARTER & ANNE C. WHITAKER WILL JOIN MALLINCKRODT BOARD PENDING SHAREHOLDER VOTE AT ANNUAL GENERAL MEETING IN MAY, 2018​.  Full Article

Angus Russell To Succeed Melvin Booth As Mallinckrodt Board Chairman In May 2018
Wednesday, 4 Apr 2018 

April 4 (Reuters) - Mallinckrodt Plc ::ANGUS RUSSELL TO SUCCEED MELVIN BOOTH AS MALLINCKRODT CHAIRMAN OF THE BOARD IN MAY 2018.SAYS DIANE GULYAS TO RETIRE FROM THE BOARD.DIRECTOR DIANE GULYAS ALSO TO RETIRE FROM BOARD IN MAY 2018.  Full Article

Mallinckrodt Plc Reports Fourth Quarter Adj. EPS Of $2.01
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Mallinckrodt Plc ::REPORTS FOURTH QUARTER AND FISCAL 2017 RESULTS, ANNOUNCES 2018 GUIDANCE AND SETS 2018 STRATEGIC PRIORITIES.Q4 ADJUSTED EARNINGS PER SHARE $2.01.Q4 SALES $792.3 MILLION.Q4 GAAP EARNINGS PER SHARE $17.40 FROM CONTINUING OPERATIONS.‍ANNOUNCES 2018 GUIDANCE AND SETS 2018 STRATEGIC PRIORITIES​.‍2018 GUIDANCE FOR ADJUSTED DILUTED EARNINGS PER SHARE IS $6.00 TO $6.50​.‍$1.5 BILLION ONE-TIME BENEFIT IN QUARTER RESULTING FROM LEGAL ENTITY REORGANIZATION AND TAX REFORM​.SEES 2018 TOTAL NET SALES FOR CONTINUING OPERATIONS INCREASE 3% TO 6%.FY2018 EARNINGS PER SHARE VIEW $7.14, REVENUE VIEW $3.18 BILLION -- THOMSON REUTERS I/B/E/S.Q4 EARNINGS PER SHARE VIEW $1.69, REVENUE VIEW $774.2 MILLION -- THOMSON REUTERS I/B/E/S.‍2018 STRATEGIC INITIATIVES INCLUDE FURTHER STREAMLINING ORGANIZATION​.‍WILL CONTINUE TO "REFINE" SENIOR MANAGEMENT TEAM​ IN 2018.MALLINCKRODT SAYS SEEKS TO REDUCE ANNUAL SG&A SPEND BY $100 MILLION NO LATER THAN EARLY 2020S WHILE CONTINUING TO INCREASE RESEARCH AND DEVELOPMENT SPENDING.‍WILL PROSPECTIVELY CLASSIFY "SPECIALTY GENERICS DISPOSAL GROUP" AS DISCONTINUED OPERATIONS, WHICH INCLUDES SPECIALTY GENERICS SEGMENT​.  Full Article

Mallinckrodt Receives FDA Acceptance Of Stannsoporfin New Drug Application Filing
Friday, 23 Feb 2018 

Feb 23 (Reuters) - Mallinckrodt Plc ::MALLINCKRODT RECEIVES FDA ACCEPTANCE OF STANNSOPORFIN NEW DRUG APPLICATION FILING.MALLINCKRODT PLC - UNDER PRESCRIPTION DRUG USER FEE ACT, FDA HAS SET ITS ACTION DATE TO RESPOND TO STANNSOPORFIN NDA AS AUGUST 22, 2018.  Full Article

Mallinckrodt Says Units Entered A $600 Million Senior Secured Term Loan Facility
Tuesday, 13 Feb 2018 

Feb 13 (Reuters) - Mallinckrodt Plc ::MALLINCKRODT PLC SAYS ON FEB 13, IN CONNECTION WITH THE MERGER, UNITS OF CO ENTERED INTO A $600 MILLION SENIOR SECURED TERM LOAN FACILITY- SEC FILING.MALLINCKRODT PLC SAYS THE NEW TERM LOAN MATURES ON FEBRUARY 24, 2025.  Full Article

Mallinckrodt Will Sell Recothrom, Preveleak To Baxter for $185 Mln
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Mallinckrodt Plc :MALLINCKRODT WILL SELL RECOTHROM® AND PREVELEAK® TO BAXTER.MALLINCKRODT - TOTAL DEAL CONSIDERATION OF $185 MILLION, WITH $153 MILLION UPFRONT, INCLUDING EXISTING INVENTORY, REMAINDER IN POTENTIAL MILESTONE PAYMENTS.MALLINCKRODT PLC - WILL RETAIN RAPLIXA FOR TOPICAL USE AND IS EVALUATING STRATEGIC OPTIONS FOR THIS PRODUCT.MALLINCKRODT - ‍ SALE IS ANTICIPATED TO DILUTE CO'S ADJUSTED EARNINGS PER SHARE BY $0.10 TO $0.15 IN 2018, WHICH WILL BE OFFSET BY SHARES REPURCHASED DURING Q4 2017​.MALLINCKRODT PLC - COMPANY WILL DISCONTINUE MARKETING OF RAPLIXA UPON CLOSE OF BAXTER TRANSACTION.MALLINCKRODT PLC - PROCEEDS FROM SALE WILL BE USED BY COMPANY TOWARD PAYING DOWN DEBT.MALLINCKRODT PLC - ‍WRITE-OFF FOR RAPLIXA​ WILL BE REPORTED FOR Q4 2017.  Full Article

Baxter To Acquire Recothrom, Preveleak For Upfront Payment Of About $153 Mln
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Baxter International Inc ::BAXTER ANNOUNCES AGREEMENT TO BROADEN PORTFOLIO OF INNOVATIVE SURGICAL PRODUCTS.BAXTER INTERNATIONAL - TO ACQUIRE RECOTHROM AND PREVELEAK FOR UPFRONT PAYMENT OF ABOUT $153 MILLION AND POTENTIAL CONTINGENT PAYMENTS IN FUTURE.BAXTER INTERNATIONAL - UPON CLOSING, DEAL EXPECTED TO BE MODESTLY ACCRETIVE TO BAXTER'S 2018 ADJUSTED EPS & INCREASINGLY ACCRETIVE THEREAFTER.BAXTER INTERNATIONAL - ‍PROPOSED DEAL INCLUDES TWO HEMOSTAT & SEALANT PRODUCTS, INCLUDING STAND-ALONE RECOMBINANT THROMBIN, SURGICAL SEALANT​.  Full Article

Mallinckrodt Unit Borrowed $900 Mln Under Revolving Credit Facility
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Mallinckrodt Plc ::MALLINCKRODT PLC SAYS ON DEC 29 UNIT OF CO BORROWED $900 MILLION AS A REVOLVING LOAN UNDER THE REVOLVING CREDIT FACILITY -SEC FILING.MALLINCKRODT PLC - PURSUANT TO TERMS OF CREDIT AGREEMENT, REVOLVING LOAN MATURES ON FEB 28 2022.  Full Article

Mallinckrodt To Buy Sucampo Pharmaceuticals For About $1.2 Bln
Tuesday, 26 Dec 2017 

Dec 26 (Reuters) - Mallinckrodt Plc ::MALLINCKRODT TO ACQUIRE SUCAMPO PHARMACEUTICALS FOR APPROXIMATELY $1.2 BILLION.MALLINCKRODT - ‍TRANSACTION WAS APPROVED BY BOARDS OF DIRECTORS OF BOTH COMPANIES​ .MALLINCKRODT PLC - MALLINCKRODT TO COMMENCE CASH TENDER OFFER FOR $18.00 PER SHARE, WITH SUPPORT FROM KEY SUCAMPO SHAREHOLDERS.MALLINCKRODT SAYS EXPECTS ACCRETION TO 2018 ADJUSTED DILUTED EARNINGS PER SHARE OF AT LEAST $0.30 AS RESULTS OF DEAL.MALLINCKRODT - DEAL EXPECTED TO BE FUNDED THROUGH BORROWINGS UNDER CO'S EXISTING REVOLVING CREDIT FACILITY, NEW SECURED TERM LOAN FACILITY, CASH ON HAND.MALLINCKRODT PLC - FOLLOWING DEAL, CO INTENDS TO UTILIZE "SIGNIFICANT" CASH GENERATION TO FOCUS ON REDUCING OUTSTANDING DEBT OVER TIME.MALLINCKRODT SAYS EXPECTS ACCRETION TO 2018 ADJUSTED DILUTED EPS OF AT LEAST $0.30; AT LEAST DOUBLE THAT IN 2019, ASSUMING DEAL CLOSES IN Q1 2018.  Full Article

Mallinckrodt Says TCJA Is Expected To Have A Neutral To Slightly Positive Impact On Adj Tax Expense Of Co
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Mallinckrodt Plc ::MALLINCKRODT PLC SAYS TCJA IS EXPECTED TO HAVE A NEUTRAL TO SLIGHTLY POSITIVE IMPACT ON NON-GAAP ADJUSTED TAX EXPENSE OF CO - SEC FILING.MALLINCKRODT - ASSUMING TCJA IS ENACTED INTO LAW, ESTIMATE TCJA WILL RESULT IN DEFERRED TAX BENEFIT OF $450 MILLION-$500 MILLION TO CO.MALLINCKRODT - UNDER TCJA, CO'S INTEREST EXPENSE DEDUCTION IN U.S. TO BE LIMITED TO ABOUT 50% OF EBITDA OF U.S. SUBSIDIARIES THROUGH SEPTEMBER 28, 2018.MALLINCKRODT- UNDER TCJA,INTEREST EXPENSE DEDUCTION IN U.S. EXPECTED TO BE LIMITED TO ABOUT 30% OF EBITDA OF U.S. SUBSIDIARIES THROUGH DEC. 31, 2021.  Full Article

UPDATE 2-Trump administration proposes production quota cuts for six opioids

WASHINGTON/NEW YORK, Aug 16 The Trump administration on Thursday proposed that U.S. drugmakers cut production quotas of the six most abused opioids by 10 percent next year to fight a nationwide addiction crisis.